It was a great pleasure to meet with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the impact in the use of CGRP antagonists in migraine therapy.
The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
Questions:
- What has been the impact of small‐molecule, oral calcitonin gene‐related peptide receptor (CGRP) antagonists such as ubrogepant on migraine therapy? (0:14)
- What is the rationale for combining ubrogepant with an anti-CGRP monoclonal antibody (mAb)? (1:28)
- What is known about the safety of coadministering these two agents? (3:10)
Disclosures: Richard Lipton reports receives research support from the NIH, FDA as well as the National Headache Foundation and the Marx Foundation; and also receives research support from Allergan/Abbvie, Amgen, Eli Lilly and Electrocore. Richard Lipton receives personal fees as a consultant or advisor from from Allergan/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy’s, GlaxoSmithKline, Grifols, Impel NeuroPharma, Novartis, Lundbeck, Merck, and Teva Pharmaceuticals; and holds stock or options in Biohaven Holdings and CtrlM Health.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
